Cartesian Therapeutics, INC 10-Q quarterly reports

Cartesian Therapeutics, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing progress in its autoimmune disease cell therapy development, securing new debt financing, and continued operational losses.

Cartesian Therapeutics reported a wider net loss for Q1 2026, primarily driven by an increase in the fair value of its contingent value right liability, alongside increased R&D expenses.

Cartesian Therapeutics reported an increased net loss for the third quarter of 2025, driven by higher research and development expenses, despite a reduced net loss for the nine-month period due to fair value adjustments.

Cartesian Therapeutics reported a net income of $15.9 million for Q2 2025, driven by fair value adjustments, despite a significant drop in collaboration revenue.

Cartesian Therapeutics announces its Q1 2025 financial results, highlighting a decrease in net loss compared to the previous year and the completion of a contingent value right (CVR) distribution.

Cartesian Therapeutics' Q3 2024 report reveals a net loss of $24.2 million, impacted by a substantial increase in the contingent value right liability, despite a rise in collaboration revenue.

Cartesian Therapeutics saw a significant increase in revenue in the second quarter of 2024, driven by a $30 million milestone payment, while also reporting a net loss for the first half of the year.

Cartesian Therapeutics' first quarter 2024 results show a net loss of $56.8 million, primarily due to a significant increase in the fair value of the contingent value right liability.